Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arcturus Therapeutics Ltd 10285 SCIENCE CENTER DRIVE SAN DIEGO CA 92121 USA

www.arcturusrx.com Employees: 111 P: 858-900-2660

Sector:

Medical

Description:

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.

Key Statistics

Overview:

Market Capitalization, $K 196,119
Enterprise Value, $K -34,791
Shares Outstanding, K 28,423
Float, K 24,074
% Float 84.70%
Short Interest, K 5,938
Short Float 20.90%
Days to Cover 10.80
Short Volume Ratio 0.74
% of Insider Shareholders 15.30%
% of Institutional Shareholders 94.54%

Financials:

Annual Sales, $ 82,030 K
Annual Net Income, $ -65,780 K
Last Quarter Sales, $ 7,200 K
Last Quarter Net Income, $ -29,080 K
EBIT, $ -76,270 K
EBITDA, $ -73,240 K

Growth:

1-Year Return -39.64%
3-Year Return -73.58%
5-Year Return -81.35%
5-Year Revenue Growth 759.85%
5-Year Earnings Growth 32.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.03 on 03/03/26
Next Earnings Date 05/11/26
Earnings Per Share ttm -2.38
EPS Growth vs. Prev Qtr -110.20%
EPS Growth vs. Prev Year 7.21%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 01/04/13
Dividend Payable Date 01/15/13
Dividend Payout Ratio 0.00%
Most Recent Split 1-7 on 11/16/17

ARCT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -29.13%
Return-on-Assets % -22.03%
Profit Margin % -80.19%
Debt/Equity 0.00
Price/Sales 2.34
Price/Cash Flow N/A
Price/Book 0.94
Book Value/Share 7.53
Interest Coverage -7.51
60-Month Beta 2.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.